User profiles for L.L. Siu
 | Lillian SiuPrincess Margaret Cancer Centre Verified email at uhn.ca Cited by 43053 |
Tumour heterogeneity in the clinic
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …
genotype variations between patients, called interpatient heterogeneity, that predict the …
Dose escalation methods in phase I cancer clinical trials
Phase I clinical trials are an essential step in the development of anticancer drugs. The main
goal of these studies is to establish the recommended dose and/or schedule of new drugs …
goal of these studies is to establish the recommended dose and/or schedule of new drugs …
[HTML][HTML] Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic
T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (…
T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (…
AACR Project GENIE: powering precision medicine through an international consortium
The AACR Project GENIE is an international data-sharing consortium focused on generating
an evidence base for precision cancer medicine by integrating clinical-grade cancer …
an evidence base for precision cancer medicine by integrating clinical-grade cancer …
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
PURPOSE: To assess the feasibility of administering OSI-774, to recommend a dose on a
protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to …
protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to …
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
The statins as anticancer agents
3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins,
have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there …
have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there …
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials
CA Townsley, R Selby, LL Siu - Journal of clinical oncology, 2005 - ascopubs.org
Purpose Older patients are significantly underrepresented in cancer clinical trials. A literature
review was undertaken to identify the barriers that impede the accrual of this vulnerable …
review was undertaken to identify the barriers that impede the accrual of this vulnerable …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
[PDF][PDF] Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis
… Siu, John Waldron, Helen Zhao, Bayardo Perez-Ordonez, Ilan Weinreb, John Kim, Jolie
Ringash, Andrew Bayley, Laura A. Dawson, Andrew Hope, John Cho, Jonathan Irish, Ralph …
Ringash, Andrew Bayley, Laura A. Dawson, Andrew Hope, John Cho, Jonathan Irish, Ralph …